ABCL is trading 5.5% up at $7.03 today, continuing a multi-day rally fueled by its recently announced preclinical collaboration with Jazz Pharmaceuticals. The deal, disclosed around June 17, involves $56 million upfront and potential milestones up to $792 million per program for the discovery of T-cell engaging multispecific antibodies. Analyst upgrades from firms like Truist Securities and Cantor Fitzgerald, citing promising Phase 1 data and the Jazz partnership, have also contributed to the positive market sentiment and sustained gains.